WEX Pharmaceuticals Inc.
TSX : WXI

WEX Pharmaceuticals Inc.

October 06, 2005 08:45 ET

WEX Pharmaceuticals Inc.: Tectin'TM' Chinese Phase IIa Study Preliminary Results

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Oct. 6, 2005) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to announce the preliminary results of its Chinese Phase IIa clinical trial of tetrodotoxin (Tectin™), an investigational drug for the management of severe cancer-related pain.

The trial was an open-label, ascending dose study involving 21 evaluable patients and was conducted in three national clinical sites in China. The two primary objectives of the study were to evaluate safety at a variety of dose levels of Tectin™ and characterize its analgesic activity. There were no serious adverse side effects reported at any dose level. The results seem to demonstrate an efficacy optimal dose similar to that identified within the Canadian development.

Based on these findings and in line with the recommendation of its clinical advisors and investigators, WEX will now proceed with the Phase IIb study in China which will involve over 200 patients. This study will be a randomized double-blind, placebo-controlled study and will be conducted in eight national clinical sites. The protocol design will be similar to the ongoing Canadian Phase IIb/III protocol study design.

"We are pleased with the increasing number of patient exposure to Tectin™ ", said Dr Jean Bourgouin, Chief Medical Officer of the Company.

"I am delighted with the progress of Tectin™ development in cancer pain management", said Dr Edge Wang, the Company's interim CEO. "I am looking forward to the next stage of development".

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat moderate to severe acute and chronic pain, symptom pain relief associated with addiction withdrawal from opioid abuse and medicines designed for local anaesthesia. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China.

Forward Looking Statements

This News Release contains forward-looking statements which may not be based on historical fact, including without limitation statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Contact Information